产品说明书

Argatroban

Print
Chemical Structure| 74863-84-6 同义名 : MCI-9038;MD-805;Argipidine
CAS号 : 74863-84-6
货号 : A178436
分子式 : C23H36N6O5S
纯度 : 99%+
分子量 : 508.634
MDL号 : MFCD23102419
存储条件：

粉末 Keep in dark place,Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(206.44 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • Thrombin

    Thrombin, Ki:5-39 nM
描述 Argatroban (MD-805), targeting thrombin specifically, offers a beneficial approach to thrombus prevention without increasing the risk of bleeding. It is administered at a rate of 0.5 to 2 micrograms/kg/min as a safe anticoagulant during left heart bypass procedures for traumatic aortic ruptures accompanied by multiple organ injuries[1]. Comparatively, Argatroban (MD-805) enhances the effectiveness of reperfusion treatments with TPA in patients with acute myocardial infarction (AMI), especially those with delayed presentations. Clinical trials indicate that both major bleeding incidents and adverse clinical outcomes are less frequent in patients treated with Argatroban than those receiving heparin[2].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00603824 Heparin-Induced Thrombocytopen... 展开 >>ia 收起 << Phase 4 Withdrawn(PI relocated) - -
NCT01911624 Staphylococcus Aureus Bacterae... 展开 >>mia 收起 << Phase 2 Completed - Belgium ... 展开 >> KUleuven/UZ Gasthuisberg Leuven, Belgium, 3000 收起 <<
NCT00921856 Coronary Vasospasm ... 展开 >> Microvascular Angina Coronary Artery Disease 收起 << Not Applicable Recruiting December 2019 Germany ... 展开 >> Robert Bosch Medical Center Recruiting Stuttgart, Germany, 70376 Contact: Peter Ong, MD    +4971181016048    petereong@gmail.com    Contact: Anastasios Athanasiadis, MD    +4971181015444 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.97mL

0.39mL

0.20mL

9.83mL

1.97mL

0.98mL

19.66mL

3.93mL

1.97mL
参考文献

[1]Kawada, T., et al., Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture. Jpn J Thorac Cardiovasc Surg, 1999. 47(3): p. 104-9.

[2]Jang, I.K., et al., A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol, 1999. 33(7): p. 1879-85.